MX2016003979A - Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. - Google Patents
Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.Info
- Publication number
- MX2016003979A MX2016003979A MX2016003979A MX2016003979A MX2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A
- Authority
- MX
- Mexico
- Prior art keywords
- prophylaxis
- treatment
- lupus erythematosus
- systemic lupus
- nephritis
- Prior art date
Links
- 208000005777 Lupus Nephritis Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 2
- -1 citric acid ester Chemical class 0.000 abstract 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886403P | 2013-10-03 | 2013-10-03 | |
| PCT/US2014/058738 WO2015051067A1 (en) | 2013-10-03 | 2014-10-02 | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003979A true MX2016003979A (es) | 2016-06-15 |
Family
ID=51842818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003979A MX2016003979A (es) | 2013-10-03 | 2014-10-02 | Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160250238A1 (https=) |
| EP (1) | EP3052105A1 (https=) |
| JP (1) | JP2016531886A (https=) |
| KR (1) | KR20160058886A (https=) |
| CN (1) | CN105705149A (https=) |
| BR (1) | BR112016007237A2 (https=) |
| CA (1) | CA2925935A1 (https=) |
| EA (1) | EA201690686A1 (https=) |
| MX (1) | MX2016003979A (https=) |
| WO (1) | WO2015051067A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020000092A1 (en) * | 2018-06-27 | 2020-01-02 | Algernon Pharmaceuticals Inc. | The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease |
| JP2023525259A (ja) * | 2020-05-07 | 2023-06-15 | 諾羅瑞韋株式会社 | うつ病治療のためのシクロセリンおよびペントキシフィリンの併用療法｛Ｃｙｃｌｏｓｅｒｉｎｅ ａｎｄ Ｐｅｎｔｏｘｉｆｙｌｌｉｎｅ Ｃｏｍｂｉｎａｔｉｏｎ Ｔｈｅｒａｐｙ ｆｏｒ Ｔｒｅａｔｍｅｎｔ ｏｆ Ｄｅｐｒｅｓｓｉｏｎ｝ |
| CN121041156A (zh) * | 2025-08-27 | 2025-12-02 | 复皙药业(上海)有限公司 | 含有替普瑞酮的具有祛红功效的膏霜及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| JP4162491B2 (ja) | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
| AU2007357338B2 (en) * | 2007-08-06 | 2014-03-20 | Takeda Pharmaceutical Company Limited | Proteasome inhibitors |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| CA2727862C (en) * | 2008-06-17 | 2016-04-19 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| US8513218B2 (en) | 2010-03-31 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| TW201309303A (zh) | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| US20140121182A1 (en) * | 2011-06-22 | 2014-05-01 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
-
2014
- 2014-10-02 MX MX2016003979A patent/MX2016003979A/es unknown
- 2014-10-02 US US15/026,417 patent/US20160250238A1/en not_active Abandoned
- 2014-10-02 JP JP2016519782A patent/JP2016531886A/ja active Pending
- 2014-10-02 BR BR112016007237A patent/BR112016007237A2/pt not_active IP Right Cessation
- 2014-10-02 CA CA2925935A patent/CA2925935A1/en not_active Abandoned
- 2014-10-02 WO PCT/US2014/058738 patent/WO2015051067A1/en not_active Ceased
- 2014-10-02 CN CN201480060987.4A patent/CN105705149A/zh active Pending
- 2014-10-02 EP EP14790872.7A patent/EP3052105A1/en not_active Withdrawn
- 2014-10-02 EA EA201690686A patent/EA201690686A1/ru unknown
- 2014-10-02 KR KR1020167010114A patent/KR20160058886A/ko not_active Withdrawn
-
2017
- 2017-12-12 US US15/838,595 patent/US20180099000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160250238A1 (en) | 2016-09-01 |
| CN105705149A (zh) | 2016-06-22 |
| WO2015051067A1 (en) | 2015-04-09 |
| KR20160058886A (ko) | 2016-05-25 |
| EA201690686A1 (ru) | 2016-08-31 |
| CA2925935A1 (en) | 2015-04-09 |
| EP3052105A1 (en) | 2016-08-10 |
| BR112016007237A2 (pt) | 2017-09-12 |
| US20180099000A1 (en) | 2018-04-12 |
| JP2016531886A (ja) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200011B1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| PH12020500286A1 (en) | Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases | |
| PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
| IL245117B (en) | Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| NZ702967A (en) | Diclofenac formulations | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| UA115811C2 (uk) | Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| IN2015DN01023A (https=) | ||
| MX376029B (es) | Compuestos de isoindol. | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| MX2016003979A (es) | Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. | |
| EP4219534A3 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX2015007862A (es) | Derivado de amida del acido cinamico. | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| MX2015013911A (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| WO2014203074A3 (en) | Use of unacylated ghrelin, fragments and analogs thereof as antioxidant | |
| HK1227698A1 (en) | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis | |
| IN2013MU03428A (https=) | ||
| MX2016002139A (es) | Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo. |